Collegium Pharmaceutical (COLL) Receivables (2016 - 2026)

Collegium Pharmaceutical's Receivables history runs 11 years deep, the most recent figure standing at $248.6 million for Q1 2026.

• In Q1 2026, Receivables rose 8.7% year-over-year to $248.6 million; the TTM figure through Mar 2026 stood at $248.6 million (up 8.7% YoY), while the FY2025 annual figure was $231.2 million, down 8.82% from the prior year.
• Receivables was $248.6 million for Q1 2026 at Collegium Pharmaceutical, up from $231.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $253.5 million in Q4 2024 to a low of $166.3 million in Q1 2022.
• Historically, Receivables has averaged $202.7 million across 5 years, with a median of $195.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables surged 119.21% in 2022, then retreated 15.2% in 2023.
• A 5-year view of Receivables shows it stood at $183.1 million in 2022, then declined by 1.96% to $179.5 million in 2023, then surged by 41.23% to $253.5 million in 2024, then fell by 8.82% to $231.2 million in 2025, then advanced by 7.54% to $248.6 million in 2026.
• The last three Receivables figures came in at $248.6 million (Q1 2026), $231.2 million (Q4 2025), and $233.9 million (Q3 2025), per Business Quant data.